Myelodysplastic Syndromes

Dr Abby Statler Speaks on Eligibility Criteria Exclusions for MDS Clinical Trials

February 21st 2020, 7:00pm

Our outcomes suggest that eligibility criteria for patients with MDS relevant to liver function, renal function, and comorbidities may be relaxed, especially for those who have minor renal function abnormalities who have shown to have similar clinical outcomes to those without such abnormalities, said Abby Statler, PhD, MPH, MA, research associate at Cleveland Clinic.

Chemotherapy for Solid Tumors Associated With Increased Risk of AML, MDS

December 28th 2018, 8:15pm

Article

Patients who are treated with chemotherapy for their solid tumors have an increased risk of therapy-related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML) despite advances in chemotherapy regimens, according to a new study in JAMA Oncology.

Early Data Suggests CC-486 Relatively Safe, Effective in Thrombocytopenic Patients With MDS

November 21st 2018, 12:22am

Article

There have been few therapeutic options for treating thrombocytopenia in MDS patients. Now, early phase data suggest that CC-486 (oral azacytidine, an investigational drug sponsored by Celgene) is a relatively safe and effective treatment for thrombocytopenic patients with MDS.